Literature DB >> 2826541

Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

J H Kehrl1, M Dukovich, G Whalen, P Katz, A S Fauci, W C Greene.   

Abstract

A novel IL-2 receptor, distinct from the Tac protein, has been identified on the surface of purified human natural killer (NK) cells by chemical cross-linking of 125I-IL-2. This protein is approximately 70,000 D in size (p70) and appears to be identical to the recently recognized second subunit of the human high affinity IL-2 receptor complex. Scatchard analysis of 125I-IL-2 binding to purified NK cells revealed approximately 2,300 p70 binding sites per cell with an apparent dissociation constant of 200 pM, a value intermediate between the previously recognized high and low affinity forms of the human IL-2 receptor. The monoclonal anti-Tac antibody did not inhibit the cross-linking of 125I-IL-2 to the p70 binding sites present on NK cells. Functionally, the addition of high concentrations of recombinant IL-2 to the enriched NK cells promoted a rapid augmentation of cytolytic activity and a more delayed increase in cellular proliferation. Anti-Tac effectively blocked the IL-2-induced proliferative response in these cells, but failed to alter the enhancement of cytotoxicity. Analysis of NK cytoplasmic RNA isolated at various time points after IL-2 stimulation revealed the rapid induction of c-myb and Tac gene expression that was also not inhibited by the anti-Tac antibody. These findings suggest that IL-2 binding to the p70 receptor constitutively expressed on the surface of NK cells may mediate both the development of increased cytolytic activity and rapid changes in gene expression. The activation of the Tac gene may in turn permit the formation of the high affinity IL-2 receptor complex (comprised of at least the Tac and p70 proteins) that appears to transduce the requisite signals involved in NK cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826541      PMCID: PMC442494          DOI: 10.1172/JCI113295

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Isolation of B and T lymphocytes by nylon fiber columns.

Authors:  C Werner; P T Klouda; M C Corréa; P Vassalli; M Jeannet
Journal:  Tissue Antigens       Date:  1977-04

3.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  Natural killer cells: characteristics and regulation of activity.

Authors:  R B Herberman; J Djeu; H D Kay; J R Ortaldo; C Riccardi; G D Bonnard; H T Holden; R Fagnani; A Santoni; P Puccetti
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

5.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein.

Authors:  L T Bich-Thuy; M Dukovich; N J Peffer; A S Fauci; J H Kehrl; W C Greene
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

8.  A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.

Authors:  M Dukovich; Y Wano; P Katz; B R Cullen; J H Kehrl; W C Greene
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

9.  Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.

Authors:  J E Talmadge; R H Wiltrout; D F Counts; R B Herberman; T McDonald; J R Ortaldo
Journal:  Cell Immunol       Date:  1986-10-15       Impact factor: 4.868

10.  Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression.

Authors:  K Teshigawara; M Maeda; K Nishino; T Nikaido; T Uchiyama; M Tsudo; Y Wano; J Yodoi
Journal:  J Mol Cell Immunol       Date:  1985
View more
  20 in total

Review 1.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  P E Lipsky; L S Davis; J J Cush; N Oppenheimer-Marks
Journal:  Springer Semin Immunopathol       Date:  1989

2.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

Authors:  L J Levitt; A Nagler; F Lee; J Abrams; M Shatsky; D Thompson
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Interleukin-2 can induce suppression of human natural killer cell cytotoxicity.

Authors:  K Hellstrand; S Hermodsson
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

5.  Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes.

Authors:  R Kradin; J Kurnick; J Gifford; C Pinto; F Preffer; D Lazarus
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

6.  Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells.

Authors:  J W Young; R M Steinman
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

Review 7.  Exercise and the immune system. Natural killer cells, interleukins and related responses.

Authors:  R J Shephard; S Rhind; P N Shek
Journal:  Sports Med       Date:  1994-11       Impact factor: 11.136

8.  Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Authors:  Wei Wang; Amy K Erbe; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; Jonathan M Weiss; James Mier; David Panka; David F McDermott; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-09-30       Impact factor: 6.968

9.  Interleukin-2 enhances the cytotoxic activity of circulating natural killer cells in patients with chronic heart failure.

Authors:  Heng-Chen Yao; Shu-Qin Liu; Ke Yu; Min Zhou; Le-Xin Wang
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

10.  Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma.

Authors:  R Mouawad; M Ichen; O Rixe; A Benhammouda; E Vuillemin; M Weil; D Khayat; C Soubrane
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.